The SPEED study is a randomized, crossover pilot study evaluating the pharmacokinetics of novel insulin formulations in adults with type 1 diabetes. The study compares two experimental insulin formulations (diluted U-200 Humalog and U-500 Humulin with sterile water, mannitol and EDTA) against commercially available U-100 Lyumjev to determine if these modifications can improve insulin onset and duration of action.
Twenty participants will complete three study visits, each separated by at least48 hours. At each visit, participants will receive one of the three insulin formulations (0.20 u/kg) via subcutaneous injection following consumption of a standardized mixed meal. Blood samples will be collected frequently over 6 hours to measure insulin concentrations and assess pharmacokinetic parameters, including time to maximum concentration (Tmax), maximum concentration (Cmax), elimination half-life, and area under the curve.
The study aims to address limitations of current insulin formulations used in automated insulin delivery systems, which are too slow to provide optimal meal coverage without pre-meal dosing. By reducing zinc content through EDTA chelation and decreasing metacresol concentration through dilution, these novel formulations may offer faster onset and shorter duration of action, potentially improving glucose control in people with type 1 diabetes using insulin pump therapy.

Start Date28 Oct 2025

Sponsor / Collaborator

Stanford University

NCT07109245

/ Not yet recruitingPhase 4IIT

Do Antipsychotics Block Insulin Action in the Brain: is it a Class Effect?

This study aimed at helping researchers understand how a medication called haloperidol can affect insulin action in the brain. Insulin is a hormone in the body that controls sugar levels in part by lowering the amount of glucose produced by the liver. After eating a meal, insulin levels go up in both the blood and the brain. Insulin in the brain has also been shown to affect the way the brain works and processes information (also known as "cognition"). Haloperidol, is an antipsychotic medication used to treat a variety of disorders such as schizophrenia spectrum disorders, bipolar disorder, and major depressive disorder, but long-term use can have metabolic side effects, like weight gain, type 2 diabetes, and cardiovascular disease. The purpose of this study is to investigate how antipsychotic medications, such as haloperidol, which carries the risk of metabolic changes, might interrupt the effect of insulin action in the brain. This will help researchers learn how to potentially reduce metabolic risk for people who take these kinds of medications in the future.

Start Date01 Sep 2025

Sponsor / Collaborator

Centre for Addiction & Mental Health

[+1]

100 Clinical Results associated with Insulin lispro

100 Translational Medicine associated with Insulin lispro

100 Patents (Medical) associated with Insulin lispro

1,214

Literatures (Medical) associated with Insulin lispro

01 Mar 2026·AMERICAN JOURNAL OF EMERGENCY MEDICINE

Comparison of Single-Dose Intravenous Insulin Regular vs. Insulin Lispro for Hyperkalemia Treatment in the Emergency Department: The SIR-LISPRO Trial

Article

Author: Sun, Jiayi ; Vakkalanka, Priyanka ; Kroll, Christian ; Said, Marianne ; Halfpap, Joseph ; Lee, Kasheng ; Khan, Mahnoor

INTRODUCTION:

Hyperkalemia is a potentially life-threatening electrolyte disturbance that is present in 2 % to 3 % of emergency department (ED) patient admissions. These patients are commonly treated with intravenous (IV) insulin. Standard of care consists of administering IV insulin regular, but other insulin formulations might be safer and/or more effective, however this has yet to be explored.

OBJECTIVE:

To evaluate the safety and effectiveness of insulin lispro and insulin regular administered intravenously for the treatment of hyperkalemia in ED patients.

METHODS:

This was a retrospective cohort study that investigated adults that were admitted to the ED of two academic centers and treated for hyperkalemia with 5 units of IV insulin therapy from January 1, 2022, through January 1, 2023. The primary outcome was the change in serum potassium within 6 h following IV insulin regular compared to IV insulin lispro. The primary safety outcome was the proportion of patients who had a hypoglycemic event (blood glucose <70 mg/dl) or required supplemental dextrose administration within 6 h post-insulin administration. Demographic, clinical characteristics, clinical management, and the outcome of change in potassium were associated using linear regression. Dichotomous outcomes pertaining to hypoglycemia were estimated using logistic regression.

RESULTS:

Among the 237 patients who met inclusion criteria, 129 received insulin regular, and 108 patients received insulin lispro. We observed a larger decrease in potassium in those that received insulin lispro compared to those that received insulin regular (uMD: -0.24; 95 %CI: -0.42, -0.06). The odds of hypoglycemia were greater among those who received insulin lispro (16 %) compared to insulin regular (7 %) (uOR: 2.49; 95 %CI: 1.08, 6.09).

CONCLUSIONS:

Intravenous insulin lispro resulted in a statistically significant reduction of serum potassium but resulted in a higher likelihood of hypoglycemia compared to IV insulin regular. Further prospective, controlled studies are needed to assess the clinical significance of the differences between insulin formulations.

01 Jan 2026·Diabetes Technology & Therapeutics

A Multicenter Study of an Investigational Extended Wear Insulin Infusion Set in Adults with Type 1 Diabetes

Article

Author: Reed, Zachariah W. ; Aleppo, Grazia ; Lehman, Alayne ; Liljenquist, David ; Muchmore, Douglas B. ; Cobry, Erin C. ; Chen, Jean ; Romey, Matt ; Carlson, Anders L. ; Beck, Roy W. ; Kollman, Craig ; Pinsker, Jordan E. ; Reed, John “Chip” ; Kruger, Davida ; Weinstock, Ruth S. ; Kudva, Yogish C. ; Putman, Melissa S. ; Ahn, David T. ; Broyles, Frances ; Lal, Rayhan A. ; Lum, John W. ; Levister, Camilla M. ; Hirsch, Irl B.

Objective::

To evaluate the function and safety of the SteadiSet™ infusion set over a continuous 7-day wear period in adults with type 1 diabetes.

Research Design and Methods::

Participants used a SteadiSet infusion set with a t:slim X2™ insulin pump with Control-IQ™ technology, and either insulin aspart or insulin lispro, for a target of 7 days for 12 consecutive wear periods. Each set removed before 7 days was adjudicated by an independent committee to assess the cause of early removal and to determine whether criteria for primary or key secondary endpoints were met.

Results::

There were 260 participants who inserted 3028 infusion sets. For the primary endpoint, the Kaplan–Meier 7-day survival estimate was 95% (95% CI 94% to 96%). For the key secondary endpoint, which expanded the reasons for a failed infusion set, the Kaplan–Meier 7-day survival estimate was 84% (95% CI 82% to 86%). For both endpoints, the P value was <0.001 compared with a prespecified survival rate of 75%. Time-in-range 70–180 mg/dL (TIR) increased through day 3 of set wear and then decreased through day 7, with the average TIR being 70.6% over the entire wear period across all infusion sets, including those that failed. An increase in total daily insulin was observed from day 4 through day 7.

Conclusions::

The 7-day survival of the SteadiSet infusion set was very high for the primary endpoint and at an acceptable level with respect to early removal for any reason related to the device.

15 Dec 2025·Clinical diabetes : a publication of the American Diabetes Association

Impact of Pharmacist-Led Deprescribing on Inappropriate Rapid-Acting Insulin Use Among Admitted Older Adults

Article

Author: Bente, Jessica ; Alvarez, Gabriela ; Minova, Ljubica

This article describes a pharmacist-led deprescribing initiative to reduce the incidence of inappropriate rapid-acting insulin use among admitted older adults at an acute care community hospital. Inappropriate use was defined as at least one episode of severe hypoglycemia (blood glucose <40 mg/dL) within 24 hours of insulin lispro administration, two or more episodes of hypoglycemia (blood glucose <70 but >40 mg/dL) within 24 hours of insulin lispro administration, or five or more held administrations of insulin lispro because of euglycemia in a 48-hour period. The initiative led to a 66% observed relative reduction of inappropriate rapid-acting insulin use over 7 months.

News (Medical) associated with Insulin lispro

10 Nov 2025

·www.mobihealthnews.com

Tandem Diabetes Care's app cleared by the FDA for Android phones

Tandem Diabetes Care , an insulin delivery and diabetes technology company, announced it received FDA clearance for the Android version of its mobile app Tandem Mobi. The system, powered by Control-IQ Plus technology, delivers Day 1 improvements, achieving 79% time in range and 90% overnight time in range, meaning the amount of time one spends in the target blood glucose range. Control-IQ technology decreases or stops basal insulin if readings from compatible continuous glucose monitoring sensors are predicted to be low. It also increases basal insulin if sensor readings are predicted to be high. It can also deliver automatic correction boluses (up to one an hour) to help prevent hyperglycemia. The mobile app aligns with Tandem's Mobi insulin pump and allows users to manage their diabetes directly from their smartphones, now including Android devices. The company said that a limited release is expected to begin in December, with commercial availability in early 2026. Once it is available, the Tandem Mobi Android app will be downloadable from the Google Play Store on compatible smartphones such as Google Pixel models 6 through 10 and Samsung Galaxy models S21 through S25. "We’re excited to bring Tandem Mobi and the best-in-class outcomes of Control-IQ plus to Android users," John Sheridan, president and CEO of Tandem Mobi, said in a statement. "This latest integration gives Android users access to the life-changing benefits of Control-IQ plus, on a system that emphasizes convenience, discretion and customization. THE LARGER TREND On Nov. 6, Tandem Mobi reported its third-quarter 2025 financial results and reaffirmed its full-year 2025 guidance. The company reported its worldwide sales increased to $249.3 million, which included sales outside of the U.S. of $73.6 million. Worldwide sales in Q3 of 2024 were $244 million, which included sales of $72.3 million outside the U.S. GAAP gross profit was $134.3 million in Q3 of this year, compared to $124.7 million in Q3 of 2024. Non-GAAP gross profit was $134.3 million in Q3 2025, compared to $124.3 million in the same period last year. GAAP operating loss was $22.9 million in the third quarter of this year, compared to $26.1 million in Q3 2024. Non-GAAP operating loss in Q3 2025 was $22.9 million, compared to $26.5 million in the same period last year. Third-quarter GAAP net loss this year was $21.2 million, compared to a net loss of $23.3 million in Q3 2024. Adjusted EBITDA was $2.8 million, or 1% of sales, in the third quarter of this year, compared to $4 million, or 2% of sales, in Q3 of 2024. The company also reported that it received FDA 510(k) clearance for extended wear use of the SteadiSet Infusion Set. In addition, it began the global commercial rollout of t:slim X2 pump integration with the FreeStyle Libre 3 Plus CGM sensor. In October, the FDA announced a recall of Tandem Mobi's insulin pump with interoperable technology. The product was recalled because the insulin pump, which includes a vibration motor that gives tactile feedback for any alerts, alarms or malfunctions, may exhibit false vibration motor failure due to a software issue causing "Malfunction 12." Malfunction 12 indicates the "Pump cannot operate, the mobile app can no longer receive data from the pump. Insulin delivery and any active continuous glucose monitor sessions have been stopped," which could result in hyperglycemia. The company said correction notices were mailed or emailed to customers. In September, Tandem Diabetes Care announced that its t:slim X2 insulin pump with Control-IQ+ automated insulin delivery technology was cleared for use with Eli Lilly and Company's Lyumjev (insulin lispro-aabc injection) ultra-rapid acting insulin in the U.S. In 2024, the t:slim X2 insulin pump , which is compatible with glucose monitoring specialist Dexcom's G7 and G6 CGM systems, was approved for sale by Health Canada. t:slim, which holds up to 300 units of insulin, features a color touchscreen and a rechargeable battery powered via a micro-USB port, can create six customized profile settings and has the ability to integrate with multiple CGM sensors. The HIMSS AI & Cybersecurity Virtual Forum is free to attend on Nov. 18. Learn more and register.

Financial StatementDrug Approval

22 Jun 2025

·www.prnewswire.com

Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans to submit efsitora for the treatment of adults with type 2 diabetes to global regulatory agencies by the end of this year INDIANAPOLIS, June 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes who used insulin for the first time, previously used daily basal insulin, and previously used daily basal insulin and mealtime insulin, respectively. In each trial, once-weekly efsitora met the primary endpoint of non-inferior A1C reduction compared to daily basal insulin. The complete results from these studies were presented at the American Diabetes Association (ADA) 85th Scientific Sessions 2025. Simultaneously, results from QWINT-1, a first-of-its-kind fixed-dose study, were published in The New England Journal of Medicine, while results from QWINT-3 and QWINT-4 were published in The Lancet. In QWINT-1, efsitora reduced A1C by 1.31% compared to 1.27% for insulin glargine at week 52 for the efficacy estimand.1,2 In the trial, efsitora was titrated to four fixed doses at four-week intervals, as needed for blood glucose control.3 In QWINT-3, efsitora reduced A1C by 0.86% compared to 0.75% for insulin degludec at week 26 for the efficacy estimand.4 In QWINT-4, efsitora reduced A1C by 1.07% compared to 1.07% for insulin glargine at week 26 for the efficacy estimand.5 In these two trials, efsitora was administered using traditional insulin dosing with adjustments based on each patient's glucose level. "The novel fixed-dose regimen used in QWINT-1 for once-weekly efsitora, which consisted of only four single-dose titration options, has the potential to facilitate and simplify insulin therapy, reducing the hesitation often associated with starting insulin to treat type 2 diabetes," said Dr. Julio Rosenstock, senior scientific advisor for Velocity Clinical Research at Medical City Dallas, clinical professor of medicine, University of Texas Southwestern Medical Center, and lead trial investigator for QWINT-1. "A simpler, once-weekly regimen with efsitora may help people with type 2 diabetes initiate and manage insulin therapy with the goal of improving blood sugar levels. Across all QWINT trials, the results showed that once-weekly efsitora controlled glucose as effectively as the most popular once-daily basal insulins." "Building on Lilly's legacy of innovation in insulin therapy, once-weekly efsitora may offer a significant advancement for people with type 2 diabetes who need insulin by eliminating over 300 injections per year," said Jeff Emmick, M.D., Ph.D., senior vice president of product development at Lilly. "These results reinforce the potential for once-weekly efsitora to help reduce the overall burden of insulin therapy through a simplified treatment approach. We look forward to working with regulatory agencies to bring this innovation to patients around the world." Across the three trials, efsitora demonstrated an overall safety profile similar to two of the most commonly used daily basal insulin therapies for the treatment of type 2 diabetes. In QWINT-1, efsitora resulted in approximately 40% fewer hypoglycemic events compared to insulin glargine, with estimated combined rates of severe or clinically significant hypoglycemic events per patient-year of exposure of 0.50 with efsitora vs. 0.88 with insulin glargine at 52 weeks. In QWINT-3, these rates were 0.84 with efsitora vs. 0.74 with insulin degludec at 78 weeks. In QWINT-4, estimated combined rates of severe or clinically significant hypoglycemic events per patient-year of exposure were 6.6 with efsitora vs. 5.9 with insulin glargine at 26 weeks. Lilly plans to submit efsitora for the treatment of adults with type 2 diabetes to global regulatory agencies by the end of this year. About the QWINT clinical trial program The QWINT Phase 3 global clinical development program for insulin efsitora alfa (efsitora) in diabetes began in 2022 and has enrolled more than 3,000 people living with type 2 diabetes across four global registration studies. QWINT-1 (NCT05662332) was a parallel-design, open-label, treat-to-target, randomized controlled clinical trial comparing the efficacy and safety of efsitora as a once-weekly basal insulin using a fixed dose escalation to daily insulin glargine for 52 weeks in insulin-naïve adults with type 2 diabetes. The trial randomized 795 participants across the U.S., Argentina and Mexico to receive efsitora once weekly or insulin glargine once daily, administered subcutaneously. Participants treated with efsitora received a starting dose of 100 units of insulin, followed by escalation to fixed dosages of 150 units, 250 units and 400 units every four weeks, as needed, until achieving a target fasting blood glucose of 80-130 mg/dL. Participants with fasting blood glucose greater than 130 mg/dL on or after 16 weeks were transferred to flexible dosing. The primary objective of the trial was to demonstrate non-inferiority in reducing A1C at week 52 with efsitora compared to daily use of insulin glargine. QWINT-3 (NCT05275400) was a multicenter, randomized, parallel-design, open-label trial comparing the efficacy and safety of efsitora as a once-weekly basal insulin to insulin degludec for 78 weeks after a three-week lead-in followed by a five-week safety follow up period, in adults with type 2 diabetes who are currently treated with basal insulin. The trial randomized 986 participants across the U.S., Argentina, Hungary, Japan, Korea, Poland, Puerto Rico, Slovakia, Spain and Taiwan to receive efsitora once weekly or insulin degludec once daily, administered subcutaneously. The primary objective of the study was to demonstrate non-inferiority in reducing A1C at week 26 with efsitora compared to insulin degludec. QWINT-4 (NCT05462756) was a parallel-design, open-label, treat-to-target, randomized controlled clinical trial comparing the efficacy and safety of efsitora as a weekly basal insulin to insulin glargine for 26 weeks in adults with type 2 diabetes who have previously been treated with basal insulin and at least two injections per day of mealtime insulin. The trial randomized 730 participants across the U.S., Argentina, Germany, India, Italy, Mexico, Puerto Rico and Spain to receive efsitora once weekly or insulin glargine once daily, both of which were administered subcutaneously along with insulin lispro. The primary objective of the trial was to demonstrate non-inferiority in reducing A1C at week 26 with efsitora compared to insulin glargine. About insulin efsitora alfa Insulin efsitora alfa (efsitora) is a once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is specifically designed for once-weekly subcutaneous administration, and with its low peak-to-trough ratio, it has the potential to provide more stable glucose levels (less glucose variability) throughout the week. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY The efficacy estimand represents the treatment effect on all participants who adhered to the study drug without initiating rescue therapy for persistent severe hyperglycemia. From a baseline of 8.20% for efsitora and 8.28% for insulin glargine. Participants treated with efsitora received a starting dose of 100 units of insulin, followed by escalation to fixed dosages of 150 units, 250 units and 400 units every four weeks, as needed, until achieving a target fasting blood glucose of 80-130 mg/dL. Participants with fasting blood glucose greater than 130 mg/dL on or after 16 weeks were transferred to flexible dosing. From a baseline of 7.80% for both efsitora and insulin degludec. From a baseline of 8.18% for both efsitora and insulin glargine. The treatment-regimen estimand represents the estimated average treatment effect regardless of treatment discontinuation or introduction of rescue therapy for persistent severe hyperglycemia. Blood glucose <54 mg/dL. Nocturnal hypoglycemia was defined as any event that occurred at night between midnight and 6 a.m. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about insulin efsitora alfa as a potential treatment for people with type 2 diabetes and the timeline for future readouts, presentations, and other milestones relating to insulin efsitora alfa and its clinical trials and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that future study results will be consistent with study results to date, that insulin efsitora alfa will prove to be a safe and effective treatment for type 2 diabetes, that insulin efsitora alfa will receive regulatory approval, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. Trademarks and Trade Names All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. SOURCE Eli Lilly and Company WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 3

20 Jun 2025

·www.einpresswire.com

Diasome Pharmaceuticals Completes Enrollment in Phase 2b OPTI-2 Trial of HDV-Insulin Lispro for Type 1 Diabetes

Phase 2b OPTI-2 trial to assess liver-targeted insulin’s ability to reduce hypoglycemia and improve postprandial control using Dexcom G7 CGM data Reaching full enrollment is an important milestone for people who rely on insulin every day, and it is a significant step forward in the continued clinical development of HDV Insulin,” — Robert Geho, CEO CLEVELAND, OH, UNITED STATES, June 19, 2025 / EINPresswire.com / -- Diasome Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company advancing portal-hepatic targeted therapies for metabolic diseases, today announced that it has completed enrollment (n = 227) in its Phase 2b OPTI-2 trial evaluating HDV-Insulin Lispro in adults with Type 1 diabetes. OPTI-2 is a randomized, double-blind, active control study comparing Diasome’s Hepatocyte Directed Vesicle (HDV™) enabled insulin lispro to conventional lispro injected subcutaneously over a six-month treatment period. All study participants are utilizing Dexcom G7 continuous glucose monitors throughout the course of treatment to capture detailed glycemic endpoints. “Reaching full enrollment is an important milestone for people who rely on insulin every day, and it is a significant step forward in the continued clinical development of HDV Insulin,” said Robert Geho, Chief Executive Officer of Diasome. “OPTI-2 is designed to show that by directing insulin to the liver, where glucose regulation begins, we can meaningfully reduce hypoglycemia and improve post-meal glycemic control. We look forward to reporting topline data early in 2026.” OPTI-2 is designed to demonstrate that liver-targeted HDV-Insulin can widen the therapeutic window of mealtime insulin by reducing the risk of hypoglycemia while maintaining glycemic control. The trial is being conducted at 26 sites in the United States. About Diasome Pharmaceuticals Diasome Pharmaceuticals is developing HDV™—a proprietary phospholipid system that delivers native peptides, proteins, and hormones directly to the portal-hepatic axis, the body’s primary site of glucose and lipid regulation that current therapies often fail to reach. The company is advancing first-in-class therapies designed to enhance the efficacy, safety, and durability of treatment for diabetes, obesity, and related metabolic disorders. Media Related Inquiry Diasome Pharmaceuticals +1 216-444-7110 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Phase 2

100 Deals associated with Insulin lispro

External Link

KEGG	Wiki	ATC	Drug Bank
D04477	Insulin lispro	A10AB04 A10AD04 A10AC04	DB00046

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus	European Union	Eli Lilly Nederland BV	30 Apr 1996
Diabetes Mellitus	Iceland	Eli Lilly Nederland BV	30 Apr 1996
Diabetes Mellitus	Liechtenstein	Eli Lilly Nederland BV	30 Apr 1996
Diabetes Mellitus	Norway	Eli Lilly Nederland BV	30 Apr 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hyperglycemia	Phase 3	United States	Eli Lilly & Co.	01 Mar 2011
Diabetes Mellitus, Type 1	Phase 3	China	Eli Lilly & Co.	01 Mar 2005
Diabetes Mellitus, Type 2	Phase 3	Mexico	Eli Lilly & Co.	01 Nov 2002
Hyperinsulinemic Hypoglycemia, Familial, 7	Phase 1	Canada	Eli Lilly & Co.	14 Feb 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05893797 (CTgov)	Not Applicable	Diabetes Mellitus, Type 2 \| Diabetes Mellitus, Type 1	36	Dexcom G6 CGM+Insulin Lispro	yffafeeghs(ceabpwuumf) = ydrzlkrfqt ccbwtfawct (gpbptnycap, rbhobjslxn - qttcenpxuf) View more	-	10 Nov 2025
NCT02293551 (CTgov)	Phase 1	-	54	lispro (Part A: Lispro (7.0 U - Reference))	mktwpuxnzv(mnchtgtozh) = pzyxgrfmed qfjyvbuhqe (ansigomtye, 21) View more	-	08 Sep 2025
				lispro (Part A: Lispro (7.28 U - Test A))	mktwpuxnzv(mnchtgtozh) = qewjjfafku qfjyvbuhqe (ansigomtye, 22) View more
NCT05262387 (CTgov)	Phase 1	Diabetes Mellitus, Type 1 \| Hyperinsulinemic Hypoglycemia, Familial, 7	25	Lyumjev (Lyumjev With 50% Basal Rate Reduction)	hpprcpthcs(nzoyreunzr) = fbviwdzied inmsrjwfvd (jgrjnkzdkn, 37.3) View more	-	03 Sep 2024
				Lyumjev (Lyumjev With 100% Basal Rate Reduction)	hpprcpthcs(nzoyreunzr) = nnlhozsbqk inmsrjwfvd (jgrjnkzdkn, 31.5) View more
NCT04200313 (Insulin-Only Bionic Pancreas Trial, CTgov)	Not Applicable	Diabetes Mellitus, Type 1	440	Usual Care (UC)	wxgndfwnko(nwysrvkxya) = uupewapymy ejndbyeuww (rituqhxcym, 10.9) View more	-	07 Nov 2023
NCT04585776 (Pubmed \| Diabetes Ther)	Phase 2	Diabetes Mellitus, Type 1	31	Insulin degludec and Lispro	jlwpoqvrpl(ytwcwjtiqd) = huhmwybdqj zftxymxujg (ndqkoxfquu ) View more	Positive	01 Nov 2023
				Ultra rapid lispro (URLi)	hbxhocmyqe(knmcfydtxy) = izatriwesm tqbymhyogb (jgcnbznlrv ) View more
NCT05067270 (CTgov)	Phase 1	Diabetes Mellitus, Type 1	40	magnesium chloride+insulin+treprostinil+sodium citrate+humalog (Treatment Given to Arm Region)	pqetmattek(ngkinvwrie) = ifwfhtxndv ikcdqpdupi (mqiyyrcyif, 182) View more	-	04 Oct 2023
				magnesium chloride+insulin+treprostinil (Treatment Given to Thigh)	pqetmattek(ngkinvwrie) = qugyrvkzjt ikcdqpdupi (mqiyyrcyif, 119) View more
NCT05262387 (EASD2023)	Phase 1	Diabetes Mellitus, Type 1	-	Ultra rapid lispro (URLi)	esbssbqvwp(cxfqduvmaa) = vdxacmsrbq jmexwothjk (bbklgziafm )	Positive	03 Oct 2023
				Lispro	esbssbqvwp(cxfqduvmaa) = xqhjrgxluv jmexwothjk (bbklgziafm )
NCT04605991 (Pubmed)	Phase 3	Diabetes Mellitus, Type 2	176	Ultra rapid lispro (URLi)	rzuieqkaeh(jgbcfsbfko) = vtsdabxsdb mwuwwbmqtd (vqwmjtasyn ) View more	-	07 Apr 2023
NCT04605991 (CTgov)	Phase 3	Diabetes Mellitus, Type 2	187	Insulin Glargine+LY900014	znpugcxtjj(ajmogwxwos) = wcryayzcbc gymimsfyys (nraldgoxik, 1.38) View more	-	03 Mar 2023
NCT03952130 (CTgov)	Phase 3	Diabetes Mellitus, Type 1	354	insulin glargine+Insulin Degludec+Insulin Lispro (Insulin Lispro (Humalog))	axalvrkryr(qedlpvozdu) = kfzlwaujzm cfjxwclgwh (wzxmkdkyky, 0.063) View more	-	08 Feb 2023
				Insulin Glargine+Insulin Degludec+LY900014 (LY900014)	axalvrkryr(qedlpvozdu) = ntohbqahke cfjxwclgwh (wzxmkdkyky, 0.064) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis